Full-Time

Associate Director

Quality Control

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$156.9k - $205.9k/yr

+ Annual Bonus Program + Long-Term Incentive Program

Sanford, NC, USA

In Person

Up to 10% domestic and limited international travel required.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
GMP
Quality Assurance (QA)
Biochemistry
Microbiology

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A minimum Bachelor's degree in life sciences is required.
  • At least 10 years of management experience leading GMP biopharmaceutical Quality Control laboratories and support areas, including QC Sample Management, Microbiology, Raw Materials, Analytical, Biochemistry, Stability, Bioassay, and/or Virology.
  • Experience managing Quality Assurance teams within biopharmaceutical manufacturing operations is required.
  • Proficiency in Empower, LIMS, ELN, LES, Microsoft Office Suite, Lean Labs, or Agile Lean is required.
  • The role requires working initially on a construction site and in a biotechn manufacturing site in Sanford, North Carolina, 100% on-site.
  • Up to 10% domestic and limited international travel is required.
Responsibilities
  • Shape functional-area strategy, influence cross-functional initiatives, and drive organizational improvements.
  • Provide technical leadership for site early-stage activities, including implementation and qualification of facilities, utilities, equipment, and analytical instruments; development and approval of user requirements; prioritization of analytical-method implementation and transfer; and implementation of selected electronic Quality Systems, including LIMS, ELN, and Empower.
  • Establish and maintain Quality Control procedures for the Site Quality Management System Laboratory Controls subsystem and develop training requirements for QC staff.
  • Lead and coordinate the compliant implementation of analytical, biochemical, and microbiological test methods through method development, qualification or optimization, validation or suitability for compendial methods, and transfer.
  • Establish a raw-materials sampling, testing, and release program in compliance with applicable regulatory requirements, including Japanese Pharmacopoeia, United States Pharmacopeia, and European Pharmacopoeia requirements.
  • Develop, implement, and ensure a compliant raw-materials supplier-qualification program.
  • Coordinate testing and reporting of laboratory results supporting the facility environmental and utility monitoring program.
  • Lead QC laboratory operations to complete validation and qualification activities for the facility, equipment, analytical instruments, and computerized systems required for commissioning and operational readiness.
  • Ensure laboratory electronic systems and records comply with 21 CFR Part 11 and ALCOA++ data-integrity requirements.
  • Hire, onboard, train, and mentor QC staff according to approved staffing plans.
  • Lead and ensure timely investigation of deviations, laboratory exceptions, and other current Good Manufacturing Practice issues, and initiate and communicate corrective and preventive actions for resolution.
  • Establish key performance indicators for QC laboratories, including out-of-specification results, invalid assays, out-of-trend results, laboratory deviations, testing turnaround times, and environmental-monitoring data trends.
  • Implement and manage the site's Contamination Control Strategy cross-functionally.
  • Assist the Quality Site Head in identifying and qualifying contracted laboratory services and contingent staffing for activities such as disinfectant efficacy studies, Mycoplasma testing, and in vitro adventitious-virus testing.
  • Lead QC laboratory activities required to respond to regulatory requests and complete regulatory and internal inspections of facility and laboratory areas.
  • Lead QC Planner, QC Microbiology, QC Analytical, and QC Bioassay Laboratory Specialists, with potential for additional positions based on business needs.
Desired Qualifications
  • A Master's degree in life science is preferred.
  • Experience starting up and operating a biopharmaceutical manufacturing facility is a plus.
  • Demonstrated experience leading and developing technical teams is desirable.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.